Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence

CHAPEL HILL, N.C., April 28 /PRNewswire/ -- The biopharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth and Merck + Schering-Plough - are now in the critical post-integration period and the acquiring companies are finding out how well they planned and executed their integration plans. It's too early for final verdicts, but clearly one M&A issue that continues to create problems for the industry is the integration of corporate cultures.

A Best Practices, LLC study found while corporate culture was rated as a highly important risk-assessment factor for a successful integration, cultural assessments were rated as a less effective pre-integration planning activity due to accuracy. Experienced integration leaders develop specific processes and approaches to assess the culture of M&A targets and then continuously assess and monitor to ensure the cultures integrate along with operations, according to our report "M&A Integration Excellence: What Bio-Pharma Companies Need to Know."

To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr997.htm.

Understanding and managing cultural issues is just one of the topics addressed in the 107-page report, which utilizes benchmark metrics and executive insights to assess current trends and future directions of bio-pharmaceutical M&A activity. The study had 26 organizations participate, including such influential companies as Pfizer, Eli Lilly, Johnson & Johnson and Abbott.

Other key topic areas in the research include:

  • Structure for Integration
  • Pre-Integration Planning Activities
  • Integration Risk Management
  • Integration Functional Excellence
  • Communications Excellence
  • Understanding & Managing Cultural Issues
  • Post-Deal Closure Integration Activities
  • Trends in M&A Integration

The pace of merger and acquisition activity in the biopharma sector remains steady as organizations continue to seek external opportunities to grow their pipelines. This data-rich report addresses key M&A issues and identifies proven practices and key success factors in the merger & acquisition integration process among pharmaceutical and biotechnology companies.

The key points this study addresses are:

  • What are the keys to successful M&A integration planning?
  • What structure, processes and best practices lead to M&A integration excellence?
  • What are the key risk factors to assess and manage in the M&A integration process?
  • How is success of the M&A integration function best measured and represented?
  • What are the critical success factors and pitfalls in the integration process?

For more information on this report, contact Jeff Zimmer at [email protected] or (919) 767-9180. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr997.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.

SOURCE Best Practices, LLC

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.